8-K

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   Washington, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

 Pursuant to Section 13 or 15(d) of the Securities Exchange
                         Act of 1934



Date of Report:         February 28, 2003
                (Date of earliest event reported)



                    Allen Organ Company
   (Exact name of registrant as specified in its charter)



    Pennsylvania                   0-275                 23-1263194
(State or other jurisdiction     (Commission             (IRS Employer
   of incorporation)              File Number)         Identification No.)


150 Locust Street, P.O. Box 36, Macungie, Pennsylvania    18062-0036
(Address of principal executive offices)                  (Zip Code)



                        610-966-2200
          (Registrants telephone number, including area code)


Item 5    Other Events

Allen Organ Company hereby incorporates by reference herein
its press release dated February 28, 2003 regarding its 2002
fourth quarter and full year results of operations, a copy
of which is included as Exhibit 99.1 attached hereto.

Item 7    Financial Statements and Exhibits

  (c) Exhibits:
        99.1   Press release dated February 28, 2003



                         Signatures

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
                                     ALLEN ORGAN COMPANY

Date:      February 28, 2003         /s/ STEVEN MARKOWITZ
                                    Steven Markowitz, President

EX-99

Exhibit 99.1
                              Allen Organ Company
                       150 Locust Street Macungie, PA 18062
                            Phone:    610-966-2200

                    NEWS RELEASE - FOR IMMEDIATE RELEASE
                                NASDAQ-AORGB

February 28, 2003            From: Nathan S. Eckhart, Vice President-Finance

Consolidated  sales  for the year ended December 31,  2002  for  Allen  Organ
Company were $67,739,548 as compared with $60,490,513 for the same period  of
2001.   The  consolidated net income was $2,685,357 or  $2.29  per  share  on
1,170,191 average outstanding shares for 2002, as compared to a net  loss  of
$(4,083,810) or $(3.49) per share on 1,170,480 average outstanding shares for
2001.

Sales  for  the  fourth  quarter  of 2002 were  $18,652,619  as  compared  to
$16,725,951 in 2001.  Net income for the fourth quarter of 2002 was  $215,822
or $0.18 per share, compared to $370,388 or $0.32 per share for 2001.

Musical  Instruments  segment  sales  increased  approximately  $73,000   and
$567,000  during  the  three  months  and  year  ended  December  31,   2002,
respectively,  when compared to the same periods in 2001.   While  the  order
rate  was slightly lower in 2002 than the same period in 2001, sales for  the
year were higher due to shipments made against the order backlog.  Electronic
Assemblies  segment  sales  increased approximately  $187,000  and  decreased
approximately $3,631,000 during the three months and year ended December  31,
2002,  respectively, when compared to the same periods in  2001.   Electronic
Assemblies  segment  sales for the year decreased due to lower  order  volume
from the Company's contract manufacturing customers that have been negatively
affected  by the economic slowdown.  Audio Equipment segment sales  decreased
slightly  during  the  three months and year ended  December  31,  2002  when
compared to the same periods in 2001.

The  Musical  Instruments operating income decreased during the three  months
and  year  ended December 31, 2002 due to changes in product mix  and  higher
operating  costs.   The Electronic Assemblies segment incurred  an  operating
loss  during the three months and year ended December 31, 2002 due  to  lower
sales volume over which to absorb fixed costs.

The  Data  Communications segment sales increased by approximately $1,742,000
and  $10,626,000  during the three months and year ended December  31,  2002,
respectively,  when  compared to the same periods in 2001.   The  2002  sales
increased  due  to  new  product introductions and  the  redirection  of  the
Company's  sales  and  marketing  efforts  away  from  CLECs  to  other  Data
Communications markets.  The Data Communications segment operating income for
the  three  months  ended  December 31, 2002 was  approximately  $108,000  as
compared  to $722,000 in the same period of 2001.  This decrease  is  due  to
lower gross margins on sales, which resulted from changes in product mix,  in
the fourth quarter of 2002.  The combination of increased sales, higher gross
margins  in  earlier quarters in 2002 and lower operating costs  resulted  in
operating income of approximately $2,017,000 for the year ended December  31,
2002, compared to an operating loss of approximately $(8,284,000) in the same
period  of  2001.  The 2001 operating loss included $1,539,000 of  additional
inventory  reserves related to discontinued products at VIR and a  charge  of
$1,930,000  to  write down the value of VIR's goodwill and for  restructuring
related  to the combination of VIR Linear Switch into Eastern Research,  Inc.
Future  sales  visibility remains limited throughout the Data  Communications
market  that  this segment serves.  In addition, this segment's  business  is
more dependent on larger individual sales that may cause sales levels to vary
more in future quarters'.

Investment  income increased slightly during the three months and year  ended
December  31, 2002 when compared to the same periods in 2001 due to  realized
gains on investments and higher invested balances that offset lower rates  of
return on invested funds.

The effective tax rate for the year ended December 31, 2002 decreased due  to
tax credits and other non-taxable items.

                                      CONSOLIDATED SALES AND EARNINGS
                               Three Months Ended             Year Ended
                            Dec. 31,       Dec. 31,     Dec. 31,     Dec. 31,
                              2002           2001         2002         2001
Sales                     $18,652,619    $16,725,951  $67,739,548  $60,490,513
Income (Loss) From
 Operations                    15,332        646,665    3,106,847   (6,963,264)
Non-Operating Income, Net     253,490        131,723      689,510      519,454
Income Tax Provision
 (Benefit)                     53,000        408,000    1,111,000   (2,360,000)
Net Income (Loss)             215,822        370,388    2,685,357   (4,083,810)

Earnings Per Share-Basic
 and Diluted                    $0.18          $0.32        $2.29       $(3.49)
Average Shares Outstanding  1,170,191      1,170,480    1,170,191    1,170,480


Allen   Organ  Company  and  its  subsidiaries  manufacture  and   distribute
electronic   keyboard   musical  instruments,  audio  equipment,   electronic
assemblies,   and   data  communication  equipment  for  the   domestic   and
international markets.

Factors that May Affect Operating Results:
The statements contained in this press release that are not purely historical
are  forward looking statements, including statements regarding the Company's
expectations, hopes, intentions or strategies regarding the future.   Forward
looking  statements include: statements regarding future products or  product
development;  statements regarding future research and  development  spending
and  the  Company's  marketing and product development  strategy,  statements
regarding   future  production  capacity.   All  forward  looking  statements
included  in  this  press release are based on information available  to  the
Company  on the date hereof, and the Company assumes no obligation to  update
any  such  forward looking statements.  Readers are cautioned  not  to  place
undue   reliance   on  these  forward  looking  statements,   which   reflect
management's  opinions only as of the date hereof.  Readers should  carefully
review  the risk factors described in other documents the Company files  from
time  to  time  with  the Securities and Exchange Commission,  including  the
Annual  Report  on  Form 10-K for the year ended December 31,  2001  and  its
Quarterly  Reports on Form 10-Q.  It is important to note that the  Company's
actual  results  could differ materially from those in such  forward  looking
statements.   Some of the factors that could cause actual results  to  differ
materially are set forth below.

The   Company   has  experienced  and  expects  to  continue  to   experience
fluctuations in its results of operations.  Factors that affect the Company's
results  of  operations  include the volume and timing  of  orders  received,
changes  in  global economics and financial markets, changes in  the  mix  of
products  sold,  market  acceptance  of  the  Company's  and  its  customer's
products,  competitive  pricing pressures, global  currency  valuations,  the
availability of raw materials that the Company purchases from suppliers,  the
Company's  ability  to  meet  increasing demand,  the  Company's  ability  to
introduce  new  products  on  a  timely basis,  the  timing  of  new  product
announcements  and introductions by the Company or its competitors,  changing
customer  requirements, delays in new product qualifications, the timing  and
extent of research and development expenses and fluctuations in manufacturing
yields.   As  a  result of the foregoing or other factors, there  can  be  no
assurance  that  the  Company will not experience  material  fluctuations  in
future  operating  results  on  a quarterly  or  annual  basis,  which  would
materially  and adversely affect the Company's business, financial  condition
and results of operations.
                                    # # #